1stOncology™: Cancer Intelligence Service – Page 12009 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Stemline Therapeutics to Present at Piper Jaffray’s 31st Annual Healthcare Conference

On November 29, 2019 Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, reported that Stemline management will present at Piper Jaffray’s 31st Annual Healthcare Conference on Tuesday, December 3rd at 1:30 PM EST at the Lotte New York Palace Hotel in New York City (Press release, Stemline Therapeutics, NOV 29, 2019, View Source [SID1234551785]). A live webcast of the presentation can be viewed on the company’s website at www.stemline.com.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

About ELZONRIS
ELZONRIS (tagraxofusp-erzs), a CD123-directed cytotoxin, is approved by the U.S. Food and Drug Administration (FDA) and commercially available in the U.S. for the treatment of adult and pediatric patients, two years or older, with blastic plasmacytoid dendritic cell neoplasm (BPDCN). For full prescribing information in the U.S., visit www.ELZONRIS.com. In Europe, a marketing authorization application (MAA) is under review by the European Medicines Agency (EMA). ELZONRIS is also being evaluated in additional clinical trials in other indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF), and acute myeloid leukemia (AML).

About BPDCN
BPDCN is an aggressive hematologic malignancy with historically poor outcomes and an area of unmet medical need. BPDCN typically presents in the bone marrow and/or skin and may also involve lymph nodes and viscera. The BPDCN cell of origin is the plasmacytoid dendritic cell (pDC) precursor. The diagnosis of BPDCN is based on the immunophenotypic diagnostic triad of CD123, CD4, and CD56, as well as other markers. For more information, please visit the BPDCN disease awareness website at www.bpdcninfo.com.

About CD123
CD123 is a cell surface target expressed on a wide range of myeloid tumors including blastic plasmacytoid dendritic cell neoplasm (BPDCN), certain myeloproliferative neoplasms (MPNs) including chronic myelomonocytic leukemia (CMML) and myelofibrosis (MF), acute myeloid leukemia (AML) (and potentially enriched in certain AML subsets), myelodysplastic syndrome (MDS), and chronic myeloid leukemia (CML). CD123 has also been reported on certain lymphoid malignancies including multiple myeloma (MM), acute lymphoid leukemia (ALL), hairy cell leukemia (HCL), Hodgkin’s lymphoma (HL), and certain Non-Hodgkin’s lymphomas (NHL). In addition, CD123 has been detected on some solid tumors as well as autoimmune disorders including cutaneous lupus and scleroderma.

MannKind Corporation to Present at the Piper Jaffray 31st Annual Healthcare Conference

On November 29, 2019 MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, reported that it will be featured as a presenting company at the Piper Jaffray 31st Annual Healthcare Conference on Tuesday, December 3, 2019 at 3:30 p.m. (ET) at the Lotte New York Palace in New York City (Press release, Mannkind, NOV 29, 2019, View Source [SID1234551784]). Presenting from the Company will be its Chief Executive Officer, Michael Castagna.

The presentation will be webcast live. Interested parties can access a link to the live webcast of the presentation from the News & Events section of the Company’s website at View Source The webcast replay will remain available for 14 days following the live presentation.

Chi-Med’s Elunate® (Fruquintinib Capsules) Included in the National Reimbursement Drug List in China

On November 28, 2019 Hutchison China MediTech reported that Elunate (fruquintinib capsules), its national class 1 targeted anticancer drug for the treatment of patients with advanced colorectal cancer ("CRC"), has been included in the updated National Reimbursement Drug List ("NRDL") released by China’s National Healthcare Security Administration ("NHSA") (Press release, Hutchison China MediTech, NOV 29, 2019, View Source [SID1234551783]).

"Elunate is Chi-Med’s first novel oncology drug commercially launched in China," commented Mr. Christian Hogg, Chief Executive Officer of Chi-Med. "The inclusion in the NRDL is a very important step forward to broaden availability and patient access to Elunate across China. We now look forward to our partner, Eli Lilly and Company ("Lilly"), to capitalize on the opportunity provided by this important government policy to accelerate the accessibility of Elunate to patients across China."

Dr. Yizhe Wang, Senior VP of Lilly China and Head of Oncology and Bio-medicines, said "We are very glad to see Elunate included in the NRDL, and we want to thank the medical experts involved in the selection process for their support. Elunate is a new treatment option for patients with advanced colorectal cancer, and has helped several thousand patients since its launch. We believe that this will further improve its affordability, help patients reduce their economic burden and improve their lives."

About the National Reimbursement Drug List (NRDL)

In recent years, the government in China has placed great importance on improving the public affordability of drug use. The National Healthcare Security Administration ("NHSA") regularly convenes a broad network of experts in medicine, pharmacology and pharmacoeconomics to identify innovative drugs to be considered for inclusion in the NRDL. This has led to rapid expansion of reimbursement of Category B drugs, which increasingly include novel oncology drugs. Reimbursement of Category B drugs requires varying degrees of copayment from patients, depending on their province of residence or type of NHSA insurance scheme enrollment.

In this 2019 update, the NHSA has added and renewed over 20 Category B oncology drugs to the NRDL, including Elunate. Effective January 1, 2020, these newly included NRDL drugs will be made available in all state-run hospital pharmacies in China and reimbursement will commence for patients included in NHSA insurance schemes.

Presentation materials to be provided at Heat Biologics, Inc. presentations

On November 29, 2019 Heat Biologics presented materials to be provided at Heat Biologics, Inc. presentations (Presentation, Heat Biologics, NOV 29, 2019, View Source [SID1234551782]).

GlycoMimetics to Present at the Piper Jaffrey 31st Annual Healthcare Conference 2019

On November 29, 2019 GlycoMimetics, Inc. (Nasdaq: GLYC) reported that Chief Executive Officer Rachel King will provide a company overview at the Piper Jaffrey 31st Annual Healthcare Conference in New York, New York, which takes place on December 3, 2019. Ms. King’s presentation is scheduled for 1:30 p.m. ET (Press release, GlycoMimetics, NOV 29, 2019, View Source [SID1234551781]).

To access the live webcast and subsequent archived recordings for this presentation, please visit the GlycoMimetics website at www.glycomimetics.com.